Statements in italics are aspirational pending additional data
1.
Gillessen S
et al. Ann Oncol
2015;26(8):1589–1604.
2.
Parker C
et al. N Engl J Med
2013;369(3):213–223.
3
.
Sartor O
et al.
EMSO 2015, Abstract 2530
Radium-223 should be used in mCRPC with symptomatic bone metastases at early signs of
disease progression after first-line SOC, but before visceral metastases develop
1
–
There is considerable cross-resistance between second-generation
anti-hormonal agents
1
A
Patients with a short life expectancy do not experience the full overall survival benefit
conferred by radium-223 treatment
2
–
Life expectancy of <6 months was an exclusion criterion in the pivotal Phase III
ALSYMPCA trial
2
C
–
The Advanced Prostate Cancer Consensus Conference (APCCC) panel does not
recommend sequential use of anti-hormonal agents (only in a minority of patients)
1
B
Selecting patients early in their disease course should be done with established prognostic
markers such as LDH, ALP, hemoglobin, and ECOG status
3
–
Patients who receive 5–6 injections of radium-223 versus 1–4 injections experience
increased overall survival
3
A
–
Patients with advanced mCRPC (≥3 prior therapies, higher ECOG PS, LDH, PSA) are less
likely to receive the recommended 6 injections of radium-223
3
B
La mayoría de los pacientes mCRPC son elegibles para el tratamiento con radium-23
